Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement. Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing. Dr Pedersen will spearhead research and development of Commit’s BiCETM technology as the Company moves towards drug candidate (DC) nomination. Commit Biologics (“Commit”), a pioneer in the activation of the […]

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, which includes 2,625,000 shares issued upon the exercise in full […]

Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D.

Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D., to the company’s board of directors. Dr. Powell currently serves as executive partner of Omega Funds and will serve as Bicara’s chairman of the board. Dr. Bowden is […]

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

Proceeds will expand visugromab’s late-stage clinical development into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international biotech investors, Canaan Partners, Bioqube Ventures, Omega Funds, Forbion Growth Fund and Gilde Healthcare to support direct path towards registration for visugromab […]

Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

First-in-class bifunctional EGFR/TGF-β inhibitor, ficerafusp alfa, in combination with pembrolizumab has demonstrated clinically meaningful anti-tumor activity and significant improvement over standard of care in HNSCC with at least 12 months of follow-up In HPV-negative HNSCC, data demonstrated an 64% ORR, 18% CR rate and mPFS of 9.8 months; median duration of response and median overall survival not yet […]

Enhanc3D Genomics appoints Hazel Jones as Chief Executive Officer

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO.   As COO and interim CEO Hazel has overseen the Company’s global business […]

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from […]

SynOx Therapeutics secures up to $35m debt financing with Hercules Capital

SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody • Provides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation • Funding is additional to recent $75m Series B financing   SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company developing emactuzumab for the […]

Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells Spin-out from Aarhus University in Denmark, a world leader […]

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour   SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was […]